Monoclonal antibody antagonizing and inhibiting the binding of human PD-1 antigen to its ligand, preparation method therefor and application thereof
A monoclonal antibody or a derivative thereof which can antagonize and inhibit the binding of human PD-1 antigen to its ligand: the amino acid sequences of CDR1, CDR 2 and CDR 3 in the light chain variable region of the antibody are shown in SEQ ID NO:3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively, while the amino acid sequences of CDR 1, CDR 2 and CDR 3 in the heavy chain variable region are shown in SEQ ID NO: 8, SEQ ID NO: 9 and SEQ ID NO: 10, respectively. A humanization preparation process for the antibody and the amino acid sequences of the heavy chain variable region and light chain variable region of the humanized antibody.
1. A monoclonal antibody antagonizing and inhibiting the binding of human PD-1 antigen to a ligand of the human PD-1 antigen, comprising: a first variable region and a second variable region, wherein the first variable region is an antibody light chain variable region having a first complementarity-determining region 1 (CDR1) with the amino acid sequence of SEQ ID NO: 3, a first complementarity-determining region 2 (CDR2) with the amino acid sequence of SEQ ID NO: 4, and a first complementarity-determining region 3 (CDR3) with the amino acid sequence of SEQ ID NO: 5, and the second variable region is an antibody heavy chain variable region having a second CDR1 with the amino acid sequence of SEQ ID NO: 8, a second CDR2 with the amino acid sequence of SEQ ID NO:9, and a second CDR3 with the amino acid sequence of SEQ ID NO: 10.
2. The monoclonal antibody according to claim 1 , wherein, the first variable region is an antibody light chain variable region having the amino acid sequence of SEQ ID NO: 11, and the second variable region is an antibody heavy chain variable region having the amino acid sequence of SEQ ID NO: 12.
3. The monoclonal antibody according to claim 1 , further comprising a human antibody light chain constant region, and a hinge region including the antibody heavy chain variable region and a human antibody heavy chain constant region, wherein the human antibody heavy chain constant region includes a constant heavy region 1 (CH1), a constant heavy region 2 (CH2) and a constant heavy region 3 (CH3).
4. The monoclonal antibody according to claim 3 , wherein, the human antibody light chain constant region is from a human antibody kappa chain or a human antibody lamda chain, and the human antibody heavy constant region is from a human subtype IgG1, IgG2, IgG3 or IgG4.
5. A DNA molecular sequence encoding the monoclonal antibody according to claim 2 , comprising: a nucleotide sequence of the antibody light chain variable region shown in SEQ ID NO: 13, and a nucleotide sequence of the antibody heavy chain variable region shown in SEQ ID NO: 14.
6. An expression vector, comprising: the DNA molecular sequence of claim 5 , and an expression regulation sequence operably linked to the DNA molecule.
7. A reconstitution host cell, formed by transforming with the expression vector of claim 6 .
8. A daughter cell of the reconstitution host cell according to claim 7 , expressing a monoclonal antibody antagonizing and inhibiting the binding of human PD-1 antigen to a ligand of the human PD-1 antigen, wherein the monoclonal antibody comprises a first variable region and a second variable region, wherein the first variable region is an antibody light chain variable region having a first complementarity-determining region 1 (CDR1) with the amino acid sequence of SEQ ID NO: 3, a first complementarity-determining region 2 (CDR2) with the amino acid sequence of SEQ ID NO: 4, and a first complementarity-determining region 3 (CDR3) with the amino acid sequence of SEQ ID NO: 5, and the second variable region is an antibody heavy chain variable region having a second CDR1 with the amino acid sequence of SEQ ID NO: 8, a second CDR2 with the amino acid sequence of SEQ ID NO:9, and a second CDR3 with the amino acid sequence of SEQ ID NO: 10.
9. A medicine comprising a pharmaceutically effective amount of the monoclonal antibody of claim 1 and a pharmaceutically acceptable carrier.
10. A method of using the medicine according to claim 9 in preparing agents for cancer treatment, comprising: using the medicine in preparing the agents for cancer treatment.
11. The method according to claim 10 , wherein the cancer is colon cancer.
12. A method for preparing the monoclonal antibody according to claim 1 , comprising the following steps:
a) providing an expression vector containing a DNA molecular sequence and an expression regulation sequence, wherein the DNA molecular sequence comprises a nucleotide sequence of the antibody light chain variable region shown in SEQ ID NO: 13, and a nucleotide sequence of the antibody heavy chain variable region shown in SEQ ID NO: 14;
b) transforming host cells with the expression vector set forth in the step a) to obtain transformed host cells;
c) culturing the transformed host cells got from the step b) in a host cell culture fluid under conditions suitable for an expression of the monoclonal antibody; and
d) getting the monoclonal antibody by the separation and purification of the host cell culture fluid with affinity chromatography.
13. The monoclonal antibody according to claim 2 , further comprising a human antibody light chain constant region, and a the hinge region including the antibody heavy chain variable region and a human antibody heavy chain constant region, wherein the human antibody heavy chain constant region includes a constant heavy region 1 (CH1), a constant heavy region 2 (CH2) and a constant heavy region 3 (CH3).
14. The daughter cell according to claim 8 , wherein, the first variable region is an antibody light chain variable region having the amino acid sequence of SEQ ID NO: 11, and the second variable region is an antibody heavy chain variable region having the amino acid sequence of SEQ ID NO: 12.
15. The medicine according to claim 9 , wherein, the first variable region is an antibody light chain variable region having the amino acid sequence of SEQ ID NO: 11, and the second variable region is an antibody heavy chain variable region having the amino acid sequence of SEQ ID NO: 12.